Literature DB >> 20560814

Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.

Marije Deutekom1, Leo G M van Rossum, Anne F van Rijn, Robert J F Laheij, Paul Fockens, Patrick M M Bossuyt, Evelien Dekker, Jan B M J Jansen.   

Abstract

OBJECTIVE: Colorectal cancer (CRC) screening programs can decide upon the type of fecal occult blood test (FOBT): the guaiac FOBT (g-FOBT) or the immunological FOBT (i-FOBT). The effectiveness of any screening program depends not only on the diagnostic performance of the screening test but also on the compliance and general acceptance of the test by the public. Any decision on the type of FOBT for CRC screening should also take acceptation and perception into account. The aim of the present study was to study differences in patient perception between i-FOBT and g-FOBT and differences in perception and participation rates among relevant subgroups in a population based study.
MATERIAL AND METHODS: Differences in patient perception of i-FOBT and g-FOBT and differences in perception and participation rates among relevant subgroups were investigated (n = 20,623) by sending a short questionnaire to all invited to the first Dutch CRC screening trial.
RESULTS: i-FOBT was perceived significantly more favorable than g-FOBT. About 1275 (32%) participants reported the g-FOBT not easy to use, not easy to perform, disgusting or shameful compared to 742 (16%) for the i-FOBT (p < 0.001). The participation rate was significantly higher in those who received i-FOBT compared to the g-FOBT group: 6159 of 10,322 (60%) versus 4839 of 10,301 (47%) (p < 0.001).
CONCLUSIONS: These findings support the selection of i-FOBT as the more appropriate test for population screening programs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20560814     DOI: 10.3109/00365521.2010.497937

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

1.  Protein levels of clusterin and glutathione synthetase in platelets allow for early detection of colorectal cancer.

Authors:  Sarah Strohkamp; Timo Gemoll; Sina Humborg; Sonja Hartwig; Stefan Lehr; Sandra Freitag-Wolf; Susanne Becker; Bo Franzén; Ralph Pries; Barbara Wollenberg; Uwe J Roblick; Hans-Peter Bruch; Tobias Keck; Gert Auer; Jens K Habermann
Journal:  Cell Mol Life Sci       Date:  2017-08-28       Impact factor: 9.261

Review 2.  New era of colorectal cancer screening.

Authors:  Maysaa El Zoghbi; Linda C Cummings
Journal:  World J Gastrointest Endosc       Date:  2016-03-10

Review 3.  Colorectal cancer screening: 20 years of development and recent progress.

Authors:  Miroslav Zavoral; Stepan Suchanek; Ondrej Majek; Premysl Fric; Petra Minarikova; Marek Minarik; Bohumil Seifert; Ladislav Dusek
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

4.  Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.

Authors:  L Sharp; L Tilson; S Whyte; A O'Ceilleachair; C Walsh; C Usher; P Tappenden; J Chilcott; A Staines; M Barry; H Comber
Journal:  Br J Cancer       Date:  2012-02-16       Impact factor: 7.640

5.  Strategies for increasing participation in mail-out colorectal cancer screening programs: a systematic review and meta-analysis.

Authors:  Belinda C Goodwin; Michael J Ireland; Sonja March; Larry Myers; Fiona Crawford-Williams; Suzanne K Chambers; Joanne F Aitken; Jeff Dunn
Journal:  Syst Rev       Date:  2019-11-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.